In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...
Clinical trials for a laser treatment targeting this common eye disease will begin in Finland next spring, and researchers hope it could become available to patients within three years. About one in ...
The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), ...
The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...
Aalto University scientists have created a laser-based treatment that uses gentle heat to stop the progression of dry macular ...
Investing.com -- Regeneron Pharmaceuticals (NASDAQ:REGN) stock rose 3% after the FDA approved its EYLEA HD injection for treating macular edema following retinal vein occlusion (RVO) with up to every ...
Support local journalism. A digital subscription is incredibly affordable and makes you the most informed person around. Click here and subscribe today Many frightening thoughts may go through your ...
No changes in protocol recommended for LUGANO and LUCIA clinical trials –– Masked safety data continues to show no safety signals, consistent ...
Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Myopic Macular Degeneration Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report ...
Beloved actress Judi Dench has previously opened up about suffering from macular degeneration, but now claims she's 'hopeless ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results